Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TS-172 QT/QTc Evaluation in Healthy Adults
NCT06837155Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Mar 2025
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of TS-172 in hyperphosphatemia (4 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: QT-interval corrected by Fridericia corrections in Holter ECGs at 24 hours. Started Mar 2025; status: completed.
02
Drugs
TS-172
03
Conditions
hyperphosphatemia
Beyond the preview
Go deeper on NCT06837155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06837155.